Chemotherapeutic and cytotoxic drugs are widely used in the treatment of cancer. In spite of
the improvements in the life quality of patients, their effectiveness is compromised by several …

Simple Summary Gastric cancer is the fifth most common tumor worldwide. In the past
couple of decades, there have been many advancements toward earlier detection and better …

A more detailed understanding of the somatic genetic events that drive gastrointestinal
adenocarcinomas is necessary to improve diagnosis and therapy. Using data from high …

Previous anti-EGFR trials in unselected patients with gastroesophageal adenocarcinoma
(GEA) were resoundingly negative. We identified EGFR amplification in 5%(19/363) of …

Gastric cancer remains difficult to cure and has a poor overall prognosis. Chemotherapy and
multimodality therapy has shown some benefit in the treatment of gastric cancer. Current …

Despite some remarkable innovations and the advent of novel molecular classifications the
prognosis of patients with advanced gastric cancer (GC) remains overall poor and current …

Monoclonal antibodies and small molecule tyrosine kinase inhibitors (TKIs) directed against
the vascular endothelial growth factor (VEGF) or its receptors have been investigated in …

Molecularly targeted therapeutic agents are constantly being developed and have been
shown to be effective in various clinical trials. One group of representative targeted …

Gastric cancer is often diagnosed at an advanced stage. Although chemotherapy prolongs
survival and improves quality of life, the survival of gastric cancer patients with advanced …

Gastric cancer is the third leading cause of malignant tumor-related mortality worldwide.
Traditional cytotoxic agents prolong the overall survival and progression-free survival of …